Synapse - Michael Morris

Results (588)

PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Halabi, S.; Dutta, S.; Chi, K. N.; Tangen, C. M.; Xuan, M.; Petrylak, D. P.; Araujo, J. C.; Fizazi, K.; Quinn, D. I.; Morris, M. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)

Meeting Abstract

Eastham, J. A.; Heller, G.; Halabi, S.; Monk, P.; Clinton, S. K.; Szmulewitz, R. Z.; Coleman, J.; Gleave, M.; Evans, C. P.; Hillman, D. W.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC)

Meeting Abstract

Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S.; Slovin, S. F.; Blinder, V. S.; Comen, E. A.; Danila, D. C.; Hoffman, D. M. J.; Kang, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)

Meeting Abstract

Autio, K. A.; Antonarakis, E. S.; Baser, R.; Stein, M. N.; Shevrin, D. H.; Vaishampayan, U. N.; Mayer, T. M.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A phase Ill trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA

Meeting Abstract

Morris, M. J.; De Wit, R.; Vogelzang, N. J.; Tagawa, S. T.; Higano, C. S.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations

Meeting Abstract

Carlo, M. I.; Kemel, Y.; Breen, K.; Cadoo, K. A.; Walsh, M. F.; Abida, W.; Autio, K. A.; Danila, D. C.; Kampel, L. J.; Morris, M. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation

Meeting Abstract

Apolo, A. B.; Rosenberg, J. E.; Kim, W. Y.; Chen, R. C.; Sonpavde, G.; Srinivas, S.; Mortazavi, A.; Watt, C.; Mallek, M.; Graap, K.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer

Journal Article

McHugh, D.; Eisenberger, M.; Heath, E. I.; Bruce, J.; Danila, D. C.; Rathkopf, D. E.; Feldman, J.; Slovin, S. F.; Anand, B.; Chu, R.; more...
Investigational New Drugs (2019)

Fulltext@MSK | Save

PD-L1 expression and clinical outcomes to cabozantinib, everolimus, and sunitinib in patients with metastatic renal cell carcinoma: Analysis of the randomized clinical trials METEOR and CABOSUN

Journal Article

Flaifel, A.; Xie, W.; Braun, D. A.; Ficial, M.; Bakouny, Z.; Nassar, A. H.; Jennings, R. B.; Escudier, B.; George, D. J.; Motzer, R. J.; more...
Clinical Cancer Research (2019)

Fulltext@MSK | Save